Description
BSE conducts Demat Auction for Settlement No. 831 dated March 4, 2026, listing shortfall quantities across 75+ scrips to be auctioned for settlement obligations.
Summary
BSE has published the Demat Auction list for Settlement No. 831, dated March 4, 2026. This auction covers shortfall quantities in demat securities across 75+ listed scrips that could not be delivered during normal settlement. Participants who failed to deliver securities in the settlement cycle are subject to close-out through this auction mechanism.
Key Points
- Settlement No. 831 auction held on March 4, 2026
- Over 75 scrips listed with varying shortfall quantities
- Quantities range from 1 share (e.g., ALEMBIC PHARMA, HDFC BANK) to large lots (e.g., EVEXIA LIFECARE: 83,932; Sylph Industries: 217,789; Viram Suvarna: 14,744)
- Covers a broad cross-section of sectors including banking, pharma, auto, energy, infrastructure, and IT
- Notable large-quantity shortfalls: Sylph Industries (217,789), EVEXIA LIFECARE (83,932), Viram Suvarna (14,744), AMPVOLTS (3,646)
Regulatory Changes
No regulatory changes. This is a routine operational notice under BSE’s existing settlement and auction framework for demat securities.
Compliance Requirements
- Sellers with shortfall positions in listed scrips must participate or face close-out at auction prices
- Buyers entitled to receive auctioned securities upon successful auction completion
- Members must comply with auction settlement obligations as per BSE bye-laws
Important Dates
- Auction Date: March 4, 2026
- Settlement No.: 831
Impact Assessment
Limited market impact. Demat auctions are a routine settlement mechanism. Individual scrips with large shortfall quantities (Sylph Industries, EVEXIA LIFECARE, Viram Suvarna) may see minor price pressure during auction. No systemic or broad market implications.
Impact Justification
Routine periodic demat auction notice for settlement shortfalls. Affects individual traders with delivery obligations but has no broad regulatory or market-wide policy impact.